Cardiotoxicity is an unavoidable concern in breast cancer patients receiving anti-HER2 therapy (Lin et al., 2021), and a recent review revealed that approximately 3%–7% of breast cancer patients receiving anti-HER2 therapy experience cardiac dysfunction of some form (Jerusalem et al., 2019). Here, ERBB2 is linked to breast cancer.